Latest news
KRYS: 2Q 2026 delivered record revenue and EPS, driven by global VYJUVEK growth and pipeline progress - TradingViewTradingView · Mon, 03 Aug 2026 19:36:15 GMTKRYS: Q2 2026 delivered 24% revenue growth, strong VYJUVEK demand, and advancing clinical milestones - TradingViewTradingView · Mon, 03 Aug 2026 14:46:23 GMTKrystal Biotech Q2 Earnings Call Highlights - TradingViewTradingView · Mon, 03 Aug 2026 14:04:36 GMTKrystal Biotech Reports Strong 2Q 2026 VYJUVEK Revenue Growth and Advances Multi-Program Genetic Medicines Pipeline - Quiver QuantitativeQuiver Quantitative · Mon, 03 Aug 2026 11:15:00 GMTKrystal Biotech Q2 revenue rises on VYJUVEK strength - TradingViewTradingView · Mon, 03 Aug 2026 11:12:32 GMTKrystal Biotech Q2 revenue rises to $119.2 million on VYJUVEK sales - Quiver QuantitativeQuiver Quantitative · Mon, 03 Aug 2026 11:06:00 GMTTrending In Gene And Cell Therapy: Vyjuvek Approval, RGX-202 And More Wilco Kelderman (v8drvE8ie5) - MshaleMshale · Fri, 31 Jul 2026 04:08:26 GMT